SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-302116
Filing Date
2023-12-22
Accepted
2023-12-22 16:08:02
Documents
13
Period of Report
2023-12-22
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d679405d8k.htm   iXBRL 8-K 30360
  Complete submission text file 0001193125-23-302116.txt   204286

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA qncx-20231222.xsd EX-101.SCH 3542
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE qncx-20231222_def.xml EX-101.DEF 15780
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE qncx-20231222_lab.xml EX-101.LAB 25567
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE qncx-20231222_pre.xml EX-101.PRE 16408
7 EXTRACTED XBRL INSTANCE DOCUMENT d679405d8k_htm.xml XML 7184
Mailing Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38890 | Film No.: 231509859
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)